Soligenix is no longer a late-stage cutaneous lymphoma story. The confirmatory FLASH2 study of HyBryte, the topical synthetic-hypericin photodynamic program that had carried the equity for years, was recommended to halt for futility in April, and the board terminated the entire development effort in June. What remains is a Princeton rare-disease microcap with cash on the balance sheet, a leftover inflammatory-disease peptide, a government-facing vaccine platform, and an explicit search for a partner, a license, or a sale. The market has already treated the lead-asset failure as decisive: capitalization sits below cash, which is the cleanest available statement that residual science is being priced as a liability rather than an asset.
The second-quarter print is the first clean look at the post-HyBryte cost base, and it is less comforting than the headline loss implies. Research spending fell as FLASH2 wound down, but general and administrative expense barely moved, and the cash balance rose only because an at-the-market facility with Rodman and Renshaw more than doubled the share count during the first half. Management still describes runway into the second quarter of twenty twenty-eight. The same liquidity note also states that substantial doubt remains about the ability to continue as a going concern, because no strategic transaction has closed and no replacement late-stage asset has been acquired. That pairing is the quarter's real tension: the burn rate can be stretched, but the franchise that justified public-market overhead is gone.
Nasdaq sent a bid-price deficiency notice in June, with a first compliance window running to early December and a possible second window if a reverse split is committed. The remaining question is whether dusquetide in Behçet's disease, the ThermoVax heat-stable vaccine work, or an acquirer that wants a listed shell can produce a path that does not depend on further cheap equity. If none of those arrive before the listing clock and the ATM both mature, the residual claim keeps shrinking even if cash still covers several quarters of overhead.